Optimal coagulation management in liver transplantation by point-of-care analysis using TEG6s in Japan

> Matsumura Muneyuki, Tokodai Kazuaki, Fujio Atsushi, Sasaki Kengo, Ogasawara Hiroyuki, Shono Yoshihiro,Ishikawa Yuki, Takido Naruhito, Unno Michiaki, Kamei Takashi

> > Tohoku University Department of Surgery



The speakers have no financial conflict of interest to disclose concerning with the presentation.

## Back ground

✓ Liver transplantation(LT) recipients are at high risk of **massive bleeding**.

- ✓ In the same time, recipients are at high risk of **vascular thrombosis** due to precarious balance of pro- and anticoagulation factors.
- ✓LT coagulation monitoring are challenging and based on standard laboratory tests (PT, aPTT, Plt, fibrinogen), but are not reflect the coagulation profile.<sup>1)</sup>
- ✓In US and Europe, thromboelastogram(TEG) are widely used and accepted as standard coagulation monitoring during LT; however, in Japan, it has not yet been widely accepted.




1) Haas and et al. British Journal of Anesthesia 2015

### Thromboelastogram (TEG)

- ✓ TEG 5000 was marketed around 1990s.
- $\checkmark$  Assesses the entire clotting process
- $\checkmark$  Generates coagulation parametes in real time





- ✓ Marketed in Japan around 2010s
- ✓ Easy to Use. Completely automated.

# Methods

 $\checkmark$  We hypothesized that TEG 6s based transfusion algorithms could reduce the amount of blood transfusion.

 $\checkmark$  We performed 32 liver transplantations over the last 3 years.


17 patients were managed based on standard laboratory tests

(SLT group:before initiation of TEG 6s).

- FFP if INR more than 1.4
- Cryoprecipitate if fibrinogen less than 150mg/dl
- Platelets if count less than 50,000/mm<sup>3</sup>
- Attendings discretion




# 15 patients were managed based on TEG 6s. (TEG 6s group) TEG 6s analysis :



- FFP if CK-R more than 10 min
- Cryoprecipitate if FF-MA less than 15 mm
- Platelet if CK-MA less than 40 mm
- Attendings discretion

Reference range





#### Patient Demographics


	SLT group		TEG 6s grou	p
Age (years)	45.9±9.4		41.4 <b>±</b> 16.4	
Weight (kg)	62.2±10.8		60.3 <b>±</b> 14.9	
Height (cm)	161.9 <b>±</b> 8.57		162.3±10.9	
Sex m/f	5/12		8/7	
Duration of Surgery (min)	919±115		680 <b>±</b> 197	
MELD score	18.7 <b>±</b> 7.69		20.3±12.9	
DDLT/LDLT	2/15		9/6	
Original Disease	Alcoholic 4	4(23%)	BA	3(20%)
	PSC 3	3(17%)	PBC	2(13%)
	Acute liver failure 3	(17%)	NASH	2(13%)
	NASH 2	2(11%)	Alcoholic	2(13%)
	PBC	1(6%)	PSC	1(7%)
	BA	1(6%)	Cryptogenic	1(7%)
	HCV	1(6%)	Wilson	1(7%)
	Budd Chiari	1(6%)	Acute liver failure	1(7%)
	AIH	1(6%)	AIH	1(7%)




 $\checkmark\,$  SLT group performed more LDLT compared to TEG 6s group.











## Discussion and Conclusion

- $\checkmark$  We reported the first pilot study using TEG 6s to manage coagulation status after LT.
- ✓ The amount of bleeding during LT and the amount of transfusion were not statistically different but tended to decrease.
- $\checkmark$  The limitation of this study was the substantial difference in background of patients.
- $\checkmark$  We will accumulate the case and find the ideal coagulation management using TEG 6s.

